ARGENTINA

On June 29, the Executive Branch, through Resolution 1114/2020 of the National Ministry of Health, removed the high cost drug Spinraza, from the company Biogen, from the Compulsory Medical Program (PMO) . The decision was taken based on a report issued by the National Committee for the Evaluation of Health Technologies (CONETEC) in November 2019.

On June 30, Resolution 202/2020 of the Ministry of Productive Development established that the maximum sale price of the active ingredient “Nusinersen (Spinraza®) 12mg/5mL”, a solution for intrathecal injection, would be US$ 27,000. In turn, it entrusted the National Commission for the Defense of Competition with an investigation of this drug.

In Resolution 1114, the Government indicated “that scientific progress, technological innovation and available information make it necessary to promote instrumental actions and mechanisms that favor the consolidation and improvement of access, quality of health care and facilitate the application of adequate allocation criteria in the use of health resources”.